Eli Lilly and Company (LLY) Yield on Cost (YOC): 0.57%
The yield on cost (YOC) for Eli Lilly and Company (LLY) is 0.57%.
LLY Yield on Cost (YOC) Metrics
YIELD ON COST (YOC)
0.57%
Yield on Cost for LLY
LLY now pays $6.46 per share a year. Measured against the price it actually traded at back then, a long-term holder is earning:
| If you bought | Price then | Yield on cost today |
|---|---|---|
| 10 years ago(2016-06-08) | $74.91 | 8.62% |
| 5 years ago(2021-06-16) | $220.76 | 2.93% |
| 3 years ago(2023-06-06) | $443.07 | 1.46% |
| 1 year ago(2025-06-10) | $807.19 | 0.80% |
| Buying today(at $1136.37) | $1136.37 | 0.57% |
If you buy today and the dividend keeps growing
Projection: starting from today's 0.57% yield, assuming the dividend keeps compounding at its historical 15.2% rate. Boards set dividends each year, so actual figures will differ.
Today
0.57%
In 3 years
1.00%
In 5 years
1.46%
In 10 years
3.78%
Yield on Cost Calculator
Try your own purchase price, dividend and growth rate for Eli Lilly and Company (LLY).
Starting Yield
0.57%
Ending YOC
4.74%
Year 15 Dividend
$53.81
Cum. Dividends Recd.
$359.30
| Year | Projected Div. / Share | YoY Dividend Hike | Yield on Cost (YOC) | Total Dividends Recd. |
|---|---|---|---|---|
| Initial | $6.46 | — | 0.57% | $0.00 |
| Year 1 | $7.44 | +15.18% | 0.65% | $7.44 |
| Year 2 | $8.57 | +15.18% | 0.75% | $16.01 |
| Year 3 | $9.87 | +15.18% | 0.87% | $25.88 |
| Year 4 | $11.37 | +15.18% | 1.00% | $37.25 |
| Year 5 | $13.10 | +15.18% | 1.15% | $50.35 |
| Year 6 | $15.08 | +15.18% | 1.33% | $65.43 |
| Year 7 | $17.37 | +15.18% | 1.53% | $82.80 |
| Year 8 | $20.01 | +15.18% | 1.76% | $102.81 |
| Year 9 | $23.05 | +15.18% | 2.03% | $125.86 |
| Year 10 | $26.55 | +15.18% | 2.34% | $152.41 |
| Year 11 | $30.58 | +15.18% | 2.69% | $182.98 |
| Year 12 | $35.22 | +15.18% | 3.10% | $218.20 |
| Year 13 | $40.56 | +15.18% | 3.57% | $258.76 |
| Year 14 | $46.72 | +15.18% | 4.11% | $305.48 |
| Year 15 | $53.81 | +15.18% | 4.74% | $359.30 |
Eli Lilly and Company Yield on Cost (YOC) Formula & Definition
Yield on cost is the dividend yield measured against your original purchase price, not today's price. As a company raises its dividend, the yield on what you actually paid keeps rising even when the market yield holds steady.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Eli Lilly and Company Yield on Cost (YOC) FAQ
- What is the yield on cost (YOC) for Eli Lilly and Company (LLY)?
- The yield on cost (YOC) for LLY stock is 0.57%.
About Eli Lilly and Company
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- David A. Ricks